HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status (Ascending) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9257 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan. 1, 2010 | In Use | ||
J9035 | Bevacizumab | Avastin | 10 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan. 1, 2005 | In Use | ||
C9449 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | April 1, 2015 | In Use | ||
J9039 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Jan. 1, 2016 | In Use | ||
J9042 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan. 1, 2013 | In Use | ||
J9055 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Jan. 1, 2005 | In Use | ||
J9415 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jan. 1, 2017 | In Use | ||
C9476 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | July 1, 2016 | In Use | ||
J9160 | Denileukin Diftitox | Ontak | 300 mcg | Immunotherapy | Cytokine | Interleukin-2 | No | 1999 | Jan. 1, 2001 | In Use | ||
J0897 | Denosumab | Prolia | 1 mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2010 | Oct. 1, 2012 | In Use | ||
NA | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | No | 2015 | In Use | |||
C9492 | Durvalumab | Imfinzi | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Oct. 1, 2017 | In Use | ||
J9176 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | Jan. 1, 2017 | In Use | ||
J9300 | Gemtuzumab ozogamicin | Mylotarg | 5 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan. 1, 2002 | In Use | ||
J9203 | Gemtuzumab ozogamicin | Mylotarg | 0.1 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan. 1, 2018 | In Use | ||
NA | Imiquimod | Aldara | 5% | Immunotherapy | Immunomodulator | Retinoic Acid Derivative | No | 1997 | In Use | |||
J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan. 1, 2009 | In Use | ||
J9214 | Interferon Alfa-2b | Intron A | 1 million units | Immunotherapy | Cytokine | Interferon | No | 1986 | Jan. 1, 1993 | In Use | ||
J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan. 1, 2009 | In Use | ||
Not yet assigned | Inotuzumab Ozogamicin | Besponsa | 0.9 mg | Immunotherapy | Drug Antibody Conjugate | CD22 | No | 2017 | In Use | |||
J9228 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jan. 1, 2012 | In Use | ||
NA | Lenalidomide | Revlimid | 5 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2005 | In Use | |||
NA | Lenalidomide | Revlimid | 10 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2005 | In Use | |||
S0177 | Levamisole | Ergamisol | 50 mg | Immunotherapy | Antiinfective Agent | antihelminitic | Yes | 1990 | 2000 | Jan. 1, 2002 | In Use | |
C9475 | Necitumumab | Portrazza | 1 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2015 | April 1, 2016 | In Use |
Found 716 results in 1 millisecond — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.